Results about: innovation
IRB Barcelona and Merus form a research collaboration to develop antibodies targeting the tumor microenvironment
The research collaboration will combine Merus’ Biclonics technology platform and unique cell and animal models at the Colorectal Cancer Laboratory led by Eduard Batlle to investigate the stroma.
ICREA researcher and group leader of the Stem Cells and Cancer Laboratory at IRB Barcelona receives an award for his work on cancer.
The prize acknowledges Salvador Aznar Benitah's contributions to transferring knowledge from basic to clinical research.
Compound IPR19, a drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.
A study at IRB Barcelona has identified the cells responsible for initiating and promoting metastasis in several types of human tumours.
Their results show that the protein CD36, which absorbs fat from the cell membrane, is an essential factor that determines whether tumour cells become metastatic.
In the absence of CD36, the human tumours analysed did not develop metastasis. In addition, the inhibition of this protein also dramatically reduced the size of existing metastases.
Mice given a high-fat diet developed the most aggressive metastases. The study reports that the metastatic process is enhanced by fat intake.
IRB Barcelona will co-develop antibodies against CD36 with the potential to treat patients.